VivoSim Labs (NASDAQ:VIVS) Releases Quarterly Earnings Results

VivoSim Labs (NASDAQ:VIVS) announced its earnings results on Wednesday. The company reported ($0.25) EPS for the quarter, FiscalAI reports. The company had revenue of $0.02 million during the quarter. VivoSim Labs had a negative return on equity of 277.62% and a negative net margin of 10,567.17%.

VivoSim Labs Trading Down 1.2%

Shares of VIVS traded down $0.00 during trading hours on Thursday, reaching $0.33. 608,886 shares of the company traded hands, compared to its average volume of 2,900,147. The stock’s fifty day moving average price is $0.80 and its 200 day moving average price is $1.38. The firm has a market cap of $1.14 million, a price-to-earnings ratio of -0.06 and a beta of 1.47. VivoSim Labs has a 12-month low of $0.31 and a 12-month high of $5.30.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, VivoSim Labs has an average rating of “Sell”.

Institutional Investors Weigh In On VivoSim Labs

A hedge fund recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP acquired a new stake in VivoSim Labs, Inc. (NASDAQ:VIVS) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs at the end of the most recent reporting period. 8.23% of the stock is owned by institutional investors and hedge funds.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.